Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 6/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21844018 | 0.81 | FPR2 (0.34) | FPR2CNR1CNR2PPARGPPARD | |
| SCHEMBL25091466 | 0.78 | USP2 (0.45) | CNR1CTSK | |
| SCHEMBL21844027 | 0.78 | FPR2 (0.35) | FPR2CNR1CNR2PPARGPPARD | |
| SCHEMBL24946124 | 0.78 | FPR2 (0.35) | FPR2CNR1CNR2PPARGPPARD | |
| SCHEMBL21917412 | 0.76 | MMP3 (0.44) | — | |
| SCHEMBL24946125 | 0.75 | FPR2 (0.34) | FPR2PPARGPPARDPPARAPIK3CD | |
| SCHEMBL12937421 | 0.71 | CA2 (0.34) | — | |
| SCHEMBL20857572 | 0.71 | LMNA (0.33) | — | |
| SCHEMBL10311712 | 0.71 | PIK3CD (0.42) | FPR2CNR1CNR2PPARGPPARD | |
| SCHEMBL28209002 | 0.71 | CA2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | FPR2 4413/4885CNR1 3133/4885CNR2 4146/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | FPR2 4413/4885CNR1 3133/4885CNR2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.